Voyager Therapeutics reported second quarter 2026 financial results on August 6, 2026. Collaboration revenue decreased to $3.2 million from $5.2 million in the prior year period due to lower activity under the Neurocrine agreement. Research and development expenses fell to $22.0 million from $31.3 million, while general and administrative expenses dropped to $7.5 million from $10.5 million following 2025 restructuring actions. The company reported a net loss of $24.5 million compared to $33.4 million in the same quarter last year. Cash, cash equivalents, and marketable securities stood at $148.8 million as of June 30, 2026, providing a runway into 2028. Clinically, Voyager expects tau PET imaging data for VY7523 and to begin dosing for gene therapy candidate VY1706 in Q4 2026. The company operates in the biotechnology industry, focusing on developing genetic medicines for neurological diseases.

Voyager Therapeutics, Inc. presented favorable GLP toxicology data for VY1706, an investigational tau silencing gene therapy for Alzheimer's disease, at the Alzheimer's Association International Conference. The data in non-human primates demonstrated a favorable tolerabilityability profile and dose-dependent CNS delivery with up to 75% lowering of tau protein in brain regions. Following FDA Investigational New Drug clearance in June 2026, the company plans to begin dosing in a multi-site, open-label, dose-escalation clinical trial in the second half of 2026. Voyager Therapeutics, Inc. is a biotechnology company developing gene therapies for neurological and other diseases.

At its 2026 Annual Meeting of Stockholders held on June 9, 2026, Voyager Therapeutics, Inc. stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of capital stock from 125,000,000 to 245,000,000 and common stock from 120,000,000 to 240,000,000. Voyager Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for genetic diseases.